{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:56:27Z","timestamp":1793217387552,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["182871\/1"],"award-info":[{"award-number":["182871\/1"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013349","name":"Lungenliga Schweiz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals Incorporated","doi-asserted-by":"publisher","award":["ISS-2021\\u2013109657"],"award-info":[{"award-number":["ISS-2021\\u2013109657"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jcf.2024.10.001","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T15:05:12Z","timestamp":1729004712000},"page":"562-570","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on the oropharyngeal metagenome in adolescents with cystic fibrosis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4108-6085","authenticated-orcid":false,"given":"Ruth","family":"Steinberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Moeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Gisler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja","family":"Mostacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Hilty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9987-2866","authenticated-orcid":false,"given":"Jakob","family":"Usemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2024.10.001_bib0001","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1164\/rccm.200304-505SO","article-title":"Pathophysiology and management of pulmonary infections in cystic fibrosis","volume":"168","author":"Gibson","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.10.001_bib0002","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0140-6736(14)61137-5","article-title":"Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis","volume":"384","author":"Sherrard","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2024.10.001_bib0003","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40168-020-00810-3","article-title":"Lung function and microbiota diversity in cystic fibrosis","volume":"8","author":"Cuthbertson","year":"2020","journal-title":"Microbiome"},{"key":"10.1016\/j.jcf.2024.10.001_bib0004","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.10.001_bib0005","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202308-1317OC","article-title":"Improvement in lung clearance index and chest ct scores with elexacaftor\/tezacaftor\/ivacaftor treatment in people with cystic fibrosis aged 12 years and older - the RECOVER study","author":"McNally","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.10.001_bib0006","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jcf.2022.12.012","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy in children with cystic fibrosis - a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI","volume":"22","author":"Streibel","year":"2023","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2024.10.001_bib0007","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1164\/rccm.202201-0219OC","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on lung clearance index and magnetic resonance imaging in patients with cystic fibrosis and one or two F508del alleles","volume":"206","author":"Graeber","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.10.001_bib0008","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00185-2021","article-title":"Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties via hydration","volume":"59","author":"Morrison","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2024.10.001_bib0009","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on mucus and mucociliary clearance in cystic fibrosis","author":"Donaldson","year":"2023","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2024.10.001_bib0010","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02153-2022","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis","volume":"62","author":"Schaupp","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2024.10.001_bib0011","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.00519-24","article-title":"Persistence and evolution of Pseudomonas aeruginosa following initiation of highly effective modulator therapy in cystic fibrosis","volume":"15","author":"Armbruster","year":"2024","journal-title":"mBio"},{"key":"10.1016\/j.jcf.2024.10.001_bib0012","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167957","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist","volume":"133","author":"Nichols","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcf.2024.10.001_bib0013","article-title":"A restructuring of microbiome niche space is associated with Elexacaftor-Tezacaftor-Ivacaftor therapy in the cystic fibrosis lung","author":"Sosinski","year":"2021","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2024.10.001_bib0014","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01454-22","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor therapy on the cystic fibrosis airway microbial metagenome","volume":"10","author":"Pallenberg","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jcf.2024.10.001_bib0015","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12931-023-02630-z","article-title":"Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor-Tezacaftor-Ivacaftor therapy","volume":"24","author":"Martin","year":"2023","journal-title":"Respir Res"},{"key":"10.1016\/j.jcf.2024.10.001_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2021.111633","article-title":"Associations of air pollution and greenness with the nasal microbiota of healthy infants: a longitudinal study","volume":"202","author":"Gisler","year":"2021","journal-title":"Environ Res"},{"key":"10.1016\/j.jcf.2024.10.001_bib0017","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of Spirometry 2019 Update. An Official American thoracic society and European respiratory society technical statement","volume":"200","author":"Graham","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.10.001_bib0018","unstructured":"Bushnell B. BBMap: a fast, accurate, splice-aware aligner. 2014."},{"key":"10.1016\/j.jcf.2024.10.001_bib0019","doi-asserted-by":"crossref","DOI":"10.1128\/msystems.00724-23","article-title":"Informed interpretation of metagenomic data by StrainPhlAn enables strain retention analyses of the upper airway microbiome","author":"Mostacci","year":"2023","journal-title":"mSystems"},{"key":"10.1016\/j.jcf.2024.10.001_bib0020","doi-asserted-by":"crossref","DOI":"10.1038\/s41587-023-01688-w","article-title":"Extending and improving metagenomic taxonomic profiling with uncharacterized species using MetaPhlAn 4","author":"Blanco-M\u00edguez","year":"2023","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jcf.2024.10.001_bib0021","series-title":"R: a language and environment for statistical computing","year":"2022"},{"key":"10.1016\/j.jcf.2024.10.001_bib0022","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41564-021-01043-2","article-title":"Early-life viral infections are associated with disadvantageous immune and microbiota profiles and recurrent respiratory infections","volume":"7","author":"de Steenhuijsen Piters","year":"2022","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.jcf.2024.10.001_bib0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1009442","article-title":"Multivariable association discovery in population-scale meta-omics studies","volume":"17","author":"Mallick","year":"2021","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.jcf.2024.10.001_bib0024","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/17476348.2021.1855980","article-title":"Development of elexacaftor - tezacaftor - ivacaftor: highly effective CFTR modulation for the majority of people with Cystic Fibrosis","volume":"15","author":"Middleton","year":"2021","journal-title":"Expert Rev Respir Med"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324017946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324017946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T22:09:29Z","timestamp":1762553369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324017946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1569199324017946"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.10.001","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on the oropharyngeal metagenome in adolescents with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}